Anti human ovarian cancer-anti CD3 bispecific antibody
US7262276B2 · kind B2 · utility
41Cited by
3References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 23, 2002 |
| Grant date | Aug 28, 2007 |
| Priority date | — |
| Expiry date | Dec 10, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/622
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides an anti-ovarian cancer bispecific antibody. Said antibody includes two polypeptide domains connected by a polypeptide linker, one is anti-ovarian cancer antibody, or its Fab fragment, single complementarity determining region (CDR) antibody or single chain Fv (scFv) and the other is anti-CD3 antibody, or its Fab fragment, single CDR antibody or scFv. The present invention also provides DNA sequences encoding said antibody, an expression vector containing said DNA sequence, and a host cell containing said expression vector.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.